Seyed Ramin Radfar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7982071/publications.pdf

Version: 2024-02-01

1039406 752256 24 454 9 20 g-index citations h-index papers 27 27 27 691 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. Basic and Clinical Neuroscience, 2020, 11, 133-150.	0.3	74
2	Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey. Frontiers in Psychiatry, 2021, 12, 639393.	1.3	52
3	A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic. Frontiers in Psychiatry, 2021, 12, 646206.	1.3	47
4	Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addiction and Health, 2014, 6, 146-54.	0.3	47
5	Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. International Journal of Drug Policy, 2010, 21, 493-500.	1.6	44
6	The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity?. Addiction, 2020, 115, 1395-1403.	1.7	41
7	Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County. Journal of Substance Abuse Treatment, 2016, 63, 66-71.	1.5	27
8	Methamphetamine Use Among Patients Undergoing Methadone Maintenance Treatment in Iran; a Threat for Harm Reduction and Treatment Strategies: A Qualitative Study. International Journal of High Risk Behaviors & Addiction, 2016, 5, .	0.1	26
9	Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. International Journal of Drug Policy, 2019, 73, 129-134.	1.6	18
10	Lead Poisoning among Opium Users in Iran: A Possible New Emerging Epidemic in the Region. Iranian Journal of Public Health, 2017, 46, 1152-1153.	0.3	9
11	Integration of Methamphetamine Harm Reduction into Opioid Harm Reduction Services in Iran: Preliminary Results of a Pilot Study. Iranian Journal of Psychiatry and Behavioral Sciences, 2017, 11, .	0.1	8
12	Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs. International Journal of Drug Policy, 2021, 93, 102908.	1.6	7
13	Behaviors Influencing Human Immunodeficiency Virus Transmission in the Context of Positive Prevention among People Living with HIV/Acquired Immunodeficiency Syndrome in Iran: A Qualitative Study. International Journal of Preventive Medicine, 2014, 5, 976-83.	0.2	7
14	Factors Influencing Access and Use of Care and Treatment Services among Iranian People Living with HIV and AIDS: A Qualitative Study. Iranian Journal of Public Health, 2016, 45, 109-11.	0.3	6
15	Integration of outpatient alcohol treatment services in substance abuse treatment centers: An introduction to the first national program in Iran. International Journal of Drug Policy, 2016, 29, 100-101.	1.6	5
16	COVID-19 and Substance Use Disorder: Study Protocol for the International Society of Addiction Medicine Practice and Policy Interest Group Global Survey. Basic and Clinical Neuroscience, 2020, 11, 155-162.	0.3	5
17	The Validity and Reliability of the Persian Version of the Leeds Dependence Questionnaire. Iranian Rehabilitation Journal, 0, , 91-96.	0.1	4
18	Acute and delayed nephropathy due to methamphetamine abuse. Journal of Nephropathology, 2020, 9, e22-e22.	0.1	3

#	Article	lF	CITATIONS
19	How Substance Use Treatment Services in Iran Survived Despite a Dual Catastrophic Situation. American Journal of Public Health, 2022, 112, S133-S135.	1.5	3
20	Prevalence of latent tuberculosis infection and HIV among people who inject drugs in Iran. Drug and Alcohol Review, 2021, 40, 572-579.	1.1	2
21	Possible Overlap of Laboratory Findings Between Patients with COVID-19 and Substance Use Disorders. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	2
22	Isolation of hepatitis C virus in norjizac vials. Hepatitis Monthly, 2010, 10, 65-6.	0.1	1
23	Integration of Outpatient Alcohol Treatment in Drug Use Disorder Treatment Centers in Iran: Study Protocol. Iranian Journal of Psychiatry and Behavioral Sciences, 2017, In Press, .	0.1	O
24	Developing the Guideline of Therapeutic Interventions for Street Children With Substance Use Disorders. Iranian Rehabilitation Journal, 0, , 425-432.	0.1	0